E-ISSN: 0975-8232; P-ISSN: 2320-5148



# PHARMACEUTICAL SCIENCES



Received on 10 September 2019; received in revised form, 04 January 2020; accepted, 04 March 2020; published 01 August 2020

## EVALUATION AND COMPARISON OF HEPATOPROTECTIVE ACTIVITY OF LIVSPLIN SYRUP AND LI- VERVE TONIC FORMULATIONS AGAINST CARBON TETRACHLORIDE INDUCED HEPATOTOXICITY IN RATS

Nargis Makabul Kagadi \*, Padma Laxmikant Ladda and Nilofar Shahnwaj Naikwade

Department of Pharmacology, Appasaheb Birnale College of Pharmacy, South Shivaji Nagar, Miraj Road, Sangli - 416416, Maharashtra, India.

### **Keywords:**

Alternative drugs, Synergistically, Beneficial, Hepatoprotective

### Correspondence to Author: Nargis Makabul Kagadi

M. Pharm,
Department of Pharmacology,
Appasaheb Birnale College of
Pharmacy, South Shivaji Nagar, Miraj
Road, Sangli - 416416, Maharashtra,
India.

**E-mail:** nargiskagadi1996@gmail.com

**ABSTRACT:** Liver diseases are a worldwide problem. Conventional drugs used in the treatment of liver diseases are sometimes inadequate and can have serious adverse effects like mild digestive problem, headache, nausea etc. It is necessary to search for alternative drugs and for treatment of liver disease to replace currently used drugs of doubtful efficacy and safety. Herbal therapies are free from side effects and toxicity, unlike allopathic medicines. Ayurvedic drugs are also acts by multiple pathways and shown full protection in liver disorders. Composition of marketed formulation Livsplin syrup (Test A) and Li- verve tonic (Test B) containing different plant extracts reported hepatoprotective and antioxidant activities. Thus these formulations may be synergistically or additively may show beneficial hepatoprotective activity with allopathic medicines. Hence, it may useful as alternative medicine to cure different kinds of liver diseases in man and animals. From our investigation, results were shown that administration of Li - verve tonic effectively protected against the loss of antioxidant activities of SOD, CAT, MDA respectively compared to control group and it is well known to serve diverse biological functions, protection of cells from oxidative damage by Reactive oxygen species & free radicals.

**INTRODUCTION:** The liver is the heaviest gland, weighing nearly about 1.4 kg in human body. It plays a vital role in regulating various physiological role and biotransformation of food, drugs, endogenous and exogenous substances <sup>1</sup>. These several biochemical reactions results in the generation of highly reactive free radicals. These free radicals attack the membrane lipids causing lipid peroxidation which alters the membrane permeability and causes tissue injury <sup>2</sup>.

QUICK RESPONSE CODE

**DOI:** 10.13040/IJPSR.0975-8232.11(8).4010-16

This article can be accessed online on www.ijpsr.com

**DOI link:** http://dx.doi.org/10.13040/IJPSR.0975-8232.11(8).4010-16

Chronic liver diseases in general are increasingly wide spread and diseases of the liver in particular are considered a global public health problem. Chronic liver disease (CLD) substantially contributes mortality and morbidity rates. Worldwide, about 500 million individuals have CLD with a viral etiology. However, CLD also has non-viral etiology including alcoholic hepatitis, fatty liver, autoimmune hepatitis, and other unidentified causes <sup>3</sup>.

Chronic hepatic diseases stand as one of the foremost health trouble worldwide, with liver cirrhosis and drug induced liver injury accounting ninth leading cause of death in western and developing countries. The common cause of acute liver diseases is drugs induced hepatotoxicity and accounts for 10% mortality <sup>4</sup>.

E-ISSN: 0975-8232; P-ISSN: 2320-5148

Liver diseases are a worldwide problem. Conventional drugs used in the treatment of liver diseases are sometimes inadequate and can have serious adverse effects like mild digestive problem, headache, nausea *etc*. It is necessary to search for alternative drugs and for treatment of liver disease to replace currently used drugs of doubtful efficacy and safety <sup>4</sup>.

Herbal- based therapeutics for liver disorders has been use in India for a long time and has been popularized world over by leading pharmaceuticals. The use of natural remedies for the treatment of liver diseases has a long history, starting with the Ayurvedic treatment, and other traditional medicines.

The 21<sup>st</sup> century has seen a paradigm shift towards the Therapeutic evaluation of herbal products in liver diseases models by carefully synergizing the strengths of the traditional systems of medicines with that of the modern concepts of evidence-based medicinal evaluation, standardization and randomization placebo controlled clinical trials to support clinical efficacy <sup>5</sup>.

Many formulations containing herbal extracts are sold in the market for liver disorders. No significant scientific data available in modern therapeutics of few marketed Ayurvedic preparation for management of liver disorders by simple and precise effective herbal drugs <sup>6</sup>.

Herbal therapies are free from side effects and toxicity, unlike allopathic medicines. Studies on hepatoprotective herbs will contribute to the benefit of the populations needing herbal treatment for hepatic disorders without involving the use of synthetic drugs and reducing the side effects of synthetic drugs. Ayurvedic drugs are also acts by multiple pathways and shown full protection in liver disorders.

Composition of marketed formulation Livsplin syrup (Test A) and Li-verve tonic (Test B) containing different plant extracts reported hepatoprotective and antioxidant activities. Thus these formulations may be synergistically or additively may show beneficial hepatoprotective activity with allopathic medicines. Hence, it may useful as alternative medicine to cure different kinds of liver diseases in man and animals.

The numbers of Ayurvedic formulations are available in the market. Among these formulation Livsplin syrup (Test A) and Li-verve tonic (Test B) has been recommended for hepatoprotective and also used as liver tonic but its pharmacological investigation is not done yet. Since, there was no scientific data available regarding hepatoprotective activity of these two Ayurvedic formulations.

Therefore, in the present investigation, carbon tetrachloride induced hepatotoxicity models was used to evaluate and compare the hepatoprotective activity of Ayurvedic formulations Livsplin syrup (Test A) and Li- verve tonic (Test B).

### **MATERIALS AND METHODS:**

**Animals:** Male/female Albino rats (Wistar strain) weighing 150-200 gm, procured from animal house of Appasahe Birnale College of Pharmacy, Sangli, were used for the study. Animals were housed in well- ventilated room at  $23 \pm 2$  °C. With humidity of 65-70% and they were fed with a standard pellet diet with tap water. Procedures involving laboratory animals were in accordance with the guidelines of the Committee for the purpose of Control and Supervision of Experiments on Animals (CPCSEA).

### List of materials used during experiments:

S. no.	Name of drug	Manufactured by
1	Silymarin	HISAR PHYTOEXTRACT
		Company Delhi.
2	Livsplin syrup (Test	Pat Pharmaceuticals Panvel,
	A)	Maharashtra.
3	Li – verve tonic	Cratus Life Care Andheri,
	(Test B)	India.

**Experimental Design for Hepatoprotective Activity:** 

Carbon Tetrachloride Induced Hepatotoxicity: Rats were divided into five groups each groups containing 6 animals.

**Group I:** Served as Normal, Received distilled water 10 ml/kg p.o. for 7 days.

**Group II:** Served as control, Received Carbon tetrachloride in dose of 2 ml/kg i.p. (CCl<sub>4</sub> in paraffin 1:1 v/v) on  $8^{th}$  day.

**Group III:** Served as Standard, Received Silymarin 100 mg/kg orally daily for 7 days and

Carbon tetrachloride in dose of 2 ml/kg i.p. (CCl<sub>4</sub> in paraffin 1:1 v/v) on 8<sup>th</sup> day.

**Group IV:** Served as (Test A) Received Livsplin Syrup 2.59 ml/kg orally daily for 7 days and Carbon tetrachloride in dose of 2 ml/kg i.p. (CCl<sub>4</sub> in paraffin 1:1 v/v) on 8<sup>th</sup> day.

**Group V:** Served as (Test B) Received Li – verve tonic 2.71 ml/kg orally daily for 7 days and Carbon tetrachloride in dose of 2 ml/kg i.p. (CCl<sub>4</sub> in paraffin 1:1 v/v) on  $8^{th}$  day

The drug solution was prepared and administered orally according to the body weight of the animals.

Assessment of Hepatoprotective Activity: In the present study the hepatoprotective activity was evaluated biochemically and histopathologically. After treatment, blood samples were removed from all animals by retro orbital puncture method. Serum was separated by centrifugation at 3000 rpm at 4

°C for 10 min and used for measurement of various biochemical markers like Alanine aminotransferase (ALT/SGPT), Aspartate aminotransferase (AST/SGOT), Serum Alkaline Phosphatase (ALP) and Total bilirubin, Total protein, using commercially available kits. All the biochemical parameters were estimated. Finally, the animals were sacrificed after 24 h of administration on the 8th day and dissected the organ liver. Weight of each liver was taken and then histopathology of the liver samples was carried out. After dissection of livers of animals from all groups further determined antioxidant parameters like Superoxide dismutase (SOD), Catalase (CAT), Malondialdehyde (MDA) 6,7,8

E-ISSN: 0975-8232; P-ISSN: 2320-5148

**Statistical Analysis:** The values were expressed as mean  $\pm$  SEM. The statistical analysis was carried out by one way analysis of variance (ANOVA) followed by Dunnet's 't' - test. P values <0.05 were considered significance.

### **RESULTS:** Hepatoprotective Activity – in CCl<sub>4</sub> Induced Hepatotoxicity:

TABLE 1: EFFECT OF LIVSPLIN SYRUP (TEST A) AND Li - VERVE TONIC (TEST B) FORMULATIONS AGAINST  $CCl_4$  INDUCED HEPATOTOXICITY

Groups	SGPT (U/L)	SGOT (U/L)	ALP	TOTAL	TOTAL	LIVER
			(U/L)	BILIRUBIN	PROTEIN	WEIGHT
				(mg/dl)	(gm/dl)	(gm)
Normal (D/W)	$44.12 \pm 0.6$	$74.21 \pm 1.4$	$141.4 \pm 0.7$	$0.6632 \pm 0.6$	$6.257 \pm 0.7$	$7.135 \pm 0.4$
10ml/kg						
Control (CCl <sub>4</sub> )	$106.3^{####} \pm 1.7$	$188^{####} \pm 0.9$	$339.1^{####} \pm 3.6$	$1.226^{####} \pm 0.7$	$3.223^{####} \pm 0.5$	$10.12 \pm 0.4$
(2 ml/kg)						
Standard	$65.41**** \pm 1.1$	89.53**** ± 1.2	$194**** \pm 0.8$	$0.7447**** \pm 0.9$	$5.54**** \pm 0.6$	$7.605 \pm 0.5$
(Silymarin)						
(100mg/kg)						
Test A	$76.65**** \pm 1.1$	$164.1**** \pm 1.5$	$283.1**** \pm 0.7$	$0.7565**** \pm 0.7$	$4.635**** \pm 0.9$	$8.115 \pm 0.8$
(Livsplin syrup)	(127.89)	(\12.71)	(\16.51)	(\\$3.52)	(†30.46)	(19.81)
(2.59 ml/kg)						
Test B	$72.51**** \pm 1.6$	$124.6**** \pm 0.9$	$246.2**** \pm 0.7$	$0.7635**** \pm 0.8$	$5.348**** \pm 0.5$	$7.635 \pm 0.5$
(Li – verve tonic)	(\131.78)	(\\$33.72)	(127.39)	(\137.41)	$(\uparrow 40.10)$	(124.55)
(2.71 ml/kg)						

n=6 animals in each group. Values are expressed as Mean  $\pm$  SEM. Significance evaluated by one-way analysis of variance (ANOVA) followed by Dunnett's test control versus all. \*<0.05 is considered as criterion for significance. SGPT- Serum Glutamate Pyruvate Transaminase, SGOT- Serum Glutamate Oxaloacetate Transaminase, ALP- Alkaline Phosphatase. #### Compared to normal (untreated). \*Level of significance p < 0.05; \*\*\*\*Level of significance p < 0.0001 compared to CCl<sub>4</sub> control. Values in bracket indicate % increase or decreae.

The serum levsels of SGPT, SGOT, ALP and T. bilirubin were significantly increased (p<0.0001) in Control while Livsplin syrup and Li – verve tonic rats treated with CCl<sub>4</sub> showed significant decrease in serum level (p<0.0001). Hepatic necrosis induced by CCl<sub>4</sub> (2ml/kg, i/p) intoxication elevated levels of serum biochemical parameters: SGPT, SGOT, ALP, T. bilirubin level and decrease the

level of T. protein. The total liver weight was also increased significantly which was indicating acute hepatocellular damage and fatty degeneration.

The results shown by the Livsplin syrup (Test A) and Li – verve tonic (Test B) Formulations are statistically significant (p<0.0001). The effects of Livsplin syrup and Li - verve tonic (Test B)

Formulations on enzymes levels, T. bilirubin and liver weight shows that Livsplin syrup (Test A) and Li – verve tonic (Test B) formulations could offer

significant degree of protection against CCl<sub>4</sub> induced hepatotoxicity

E-ISSN: 0975-8232; P-ISSN: 2320-5148

### Antioxidant Activity- in CCl<sub>4</sub> Induced Hepatotoxicity:

TABLE 2: EFFECT OF LIVSPLIN SYRUP (TEST A) AND Li - VERVE TONIC (TEST B) FORMULATIONS ON VARIOUS ANTIOXIDANT ENZYMES AGAINST CCl₄ INDUCED HEPATOTOXICITY


Groups	SOD (U/mg of protein)	CAT (U/mg of protein)	MDA (nmole/gm liver)	
Normal (D/W) 10ml/kg	$41.53 \pm 0.3$	$34.69 \pm 0.2$	$0.5885 \pm 0.4$	
Control (CCl <sub>4</sub> ) (2 ml/kg)	$9.17^{####} \pm 0.2$	$5.816^{####} \pm 0.3$	$12.67^{####} \pm 0.4$	
Standard (Silymarin) (100mg/kg)	$28.23**** \pm 0.2$	$25.15**** \pm 0.3$	$2.617**** \pm 0.7$	
Test A (Livsplin syrup)	$17.33**** \pm 0.4$	$16.61**** \pm 0.7$	$4.555**** \pm 0.6$	
(2.59  ml/kg)	(†88.98)	(†185.59)	(↓64.08)	
Test B (Li – verve tonic)	$20.58**** \pm 0.6$	$19.09**** \pm 0.5$	$3.595**** \pm 0.8$	
(2.71 ml/kg)	(†124.42)	(†228.23)	(↓71.62)	

n = 6 animals in each group. Values are expressed as Mean ± SEM. Significance evaluated by one-way analysis of variance (ANOVA) followed by Dunnett's test control versus all. \*<0.05 is considered as criterion for significance. SOD - Superoxide dismutase, CAT- Catalase, MDA- Malondialdehyde. \*Level of significance p < 0.05; \*\*\*\*Level of significance p < 0.0001 compared to CCl4 control. #### Compared to normal (untreated). Values in bracket indicate % increase or decrease.


Hepatic SOD and CAT activities in the CCl<sub>4</sub> induced group were reduced compared to normal group, while MDA activity was increased. These antioxidant activities statistically enzyme

significantly greater in the group treated with Livsplin syrup (Test A) and Li – verve tonic (Test B) formulations SOD, CAT while reduced level of MDA respectively compared to control group.

### Histopathological Studies- In CCl<sub>4</sub> Induced Hepatotoxicity.




Liver section of normal showing hepatocytes




Hydropic degeneration occurs (Reversible type of cell injury)



Infiltration by inflammatory cells and centrilobular necrosis





Li -verve tonic

Hydropic degeneration Necrosis and Inflammation does not observed

Hydropic degeneration (Reversible type of cell injury)

FIG. 1: REPRESENTATIVE PHOTOMICROGRAPHS OF HISTOPATHOLOGICAL CHANGES SHOWING EFFECT OF TEST MATERIALS ON THE RATS INTOXICATED WITH CARBON TETRACHLORIDE

**DISCUSSION:** Carbon tetrachloride is metabolized by cytochrome P-450 in endoplasmic reticulum and mitochondria with the formation of CCl<sub>3</sub>O<sup>-</sup>, a reactive oxidative free radical, which initiates lipid peroxidation. Administration of a single dose of CCl<sub>4</sub> to a rat produces, within 24 h, a centrilobular necrosis and fatty changes. The development of necrosis is associated with leakage of hepatic enzymes into serum <sup>7</sup>.

CCl<sub>4</sub> not only initiate lipid peroxidation but also reduce CAT and SOD activities, and this depletion may result from oxidative modification of these proteins. CCl<sub>4</sub> is widely used to induce liver damage because it is metabolized in hepatocytes by cytochrome P450 <sup>8, 9</sup>. Increased levels of SGPT, SGOT and ALP in serum of the CCl<sub>4</sub> treated control animals indicates liver damage as these enzymes leak out from liver into blood at the instance of tissue damage, which is always associated with hepatonecrosis. Livsplin syrup (Test A) and Li – verve tonic (Test B) results showed percentage decrease in enzyme level of SGPT (\$\frac{1}{27.89}, \$\frac{1}{31.78}\$) SGOT (\$\frac{1}{12.71}, \$\frac{1}{33.72}\$) and ALP ( $\downarrow 16.51$ ,  $\downarrow 27.39$ ) respectively, indicating protection against liver damage. ALP activity is related to functioning of the hepatocytes. Suppression of the increased ALP activity suggests the stability of biliary dysfunction in rat liver during chronic hepatic injury with CCl<sub>4</sub>.

Diminution of total protein by  $CCl_4$  is a further indication of liver damage. Livsplin syrup (Test A) and Li – verve tonic (Test B) has increased ( $\uparrow 30.46$  &  $\uparrow 40.1\%$ ) the levels of serum total protein towards respective normal value, which reveals

hepatoprotective activity. Stimulation of protein synthesis has been advanced as a contributory hepatoprotective mechanism which accelerates the regeneration process and the production of liver cells  $^9$ . Also, weight of liver was significantly increased in CCl<sub>4</sub> treated control group, but there was significant reduction observed in Livsplin syrup (Test A) and Li – verve tonic (Test B) treated groups ( $\downarrow 19.81 \& \downarrow 24.55$ ) respectively. A significant reduction in liver weight supports this finding  $^9$ .

Our results showed that administration of Livsplin syrup (Test A) and Li - verve tonic (Test B) effectively protected against the loss of antioxidant activities of SOD (†88.98, †124.42), CAT (†185.59, †228.23), MDA (\$\digma\$64.08, \$\digma\$71.62) respectively compared to control group and it is well known to serve diverse biological functions, including protection of cells from oxidative damage by Reactive Oxygen Species and free radicals.

In histopathological study, hepatocytes of normal group were shown a normal histological architecture in all models. It has been observed that CCl<sub>4</sub> causes inflammatory cells infiltration, fatty degeneration and centrilobular necrosis. These histopathological findings revels that hydropic degeneration occurs and significantly improved the structure of hepatic cells. The present study supports agreement with previous studies <sup>9</sup>. Treatment with Livsplin syrup (Test A) and Liverve tonic (Test B) hydropic degeneration occurs, which is characteristic feature of reversible cell injury indicates significantly improved the structure of hepatic cells. The liver sections of rats treated

E-ISSN: 0975-8232; P-ISSN: 2320-5148

with Livsplin syrup (Test A) and Li-verve tonic (Test B) and Silymarin along with CCl<sub>4</sub> were shown a sign of protection.

Livsplin Syrup (Test A) Contains: Boerhasavia diffusa <sup>10</sup>, Zea mays <sup>11</sup> Eclipta alba, Tecomella undulata, Aegle marmelos <sup>12</sup>, Emblica ribs, Zingiber officinale, Vitis vinifera, Terminalia chebula <sup>13</sup>, Ipomoea turpethum <sup>14</sup>.

**Li-verve tonic (Test B) Contains:** Phyllanthus niruri <sup>15</sup>, Eclipta alba, Boerhaavia diffusa <sup>10</sup>, Andrographis paniculata, Tephrosia purpurea (Linn) <sup>16</sup>, Tinospora cordifolia <sup>17</sup>, Amour rohituka, Picrorrhiza kurrooa, Zingiber officinale, Longum - pipers

Li- verve tonic (Test B) containing *Phyllanthus niruri* plant extract. The presence of phenolic compounds, glycosides, flavonoids, flavonois, polyphenols, phenolic compounds, phenylpropanoids, protein, vit. E. is present in *Phyllanthus niruri* which are known antioxidants reported by Danladi S *et al.*, (2018). The presence of all these compounds may contribute for high free radical scavenging activity. Phenolic compounds, by virtue of their hydrogen donating ability, forming aryloxyl radicals, act as free radical scavengers and quench the lipid peroxidation.

Further it has been already reported that phytochemical constituents like phenolic compounds, flavonoids are showed hepatoprotective activity in various experimental models and hence flavonoids and phenol containing herbal extracts are used in various hepatoprotective formulations <sup>4, 18</sup>.

Li-verve tonic (Test B) showed most significant effect than Livsplin syrup (Test A). The following reasons that might be responsible for significant hepatoprotective effect of Li – verve tonic (Test B) compared to Livsplin syrup (Test A).

- **1.** The dose of Li-verve tonic (Test B) (2.71 ml/kg) is more than the Livsplin syrup (Test A) (2.59 ml/kg).
- **2.** The Li-verve tonic (Test B) contains 10 number of plant extracts in its composition as compared to Livsplin syrup (Test A) contains 9 number of plant extracts. Among that 8 plants from Li-verve tonic formulation showed antioxidant property than

Livsplin syrup which contain 5 antioxidant herbal plants which showed antioxidant properties.

Li-verve tonic (Test B) contains herbal antioxidant plants namely, *Phyllanthus niruri* <sup>15</sup>, *Eclipta alba*, *Boerhaavia diffusa* <sup>10</sup>, *Tephrosia purpurea* (Linn) <sup>16</sup>, *Tinospora cordifolia* <sup>17</sup>, *Amour rohituka, Picrorrhiza kurrooa, Zingiber officinale*; that might be responsible for significant hepatoprotective activity which was also confirmed by result of biochemical and histopathological parameters of the Livsplin syrup (Test A) and Li-verve tonic (Test B) formulations.

Thus result concluded that Li-verve tonic (Test B) is most significant hepatoprotective formulation compared to Livsplin syrup (Test A).

**CONCLUSION:** The present study revealed the following conclusions:

- Livsplin syrup and Li verve tonic demonstrated a significant Hepatoprotective activity against Carbontetrachloride induced hepatotoxicity in rats.
- Moreover, Li verve tonic has shown significant Hepatoprotective activity in comparison to Livsplin syrup which is also confirmed by result of biochemical parameters and histopathological findings.

ACKNOWLEDGEMENT: Authors are thankful to Dr. Padma Ladda, Associate Professor, Department of Pharmacology, ABCP, Sangli, Maharashtra, India, Dr. Nilofar Naikwade, Professor and Head, Department of Pharmacology, ABCP, Sangli, Maharashtra, India, Tabassum Shikalgar, Assistant Professor, Department of Pharmacology, ABCP, Sangli, Maharashtra, India, and Shirish Patil, Assistant Professor, Department of Pharmacology, ABCP, Sangli for their valuable support.

### **CONFLICTS OF INTEREST: Nil**

#### **REFERENCES:**

 Sharma V, Bisht S and Singh M: Hepatoprotective and antidyslipidemic effect of Ferula asafoetida in CCl<sub>4</sub> induced hepatotoxicity and CCl<sub>4</sub> associated dyslipidemia in rats. Asian Journal of Pharmacy and Pharmacology 2018; 4(1): 61-65.

- Chaudhari G and Mahajan R: *In-vitro* hepatoprotective activity of Terminalia arjuna stem bark and its flavonoids against CCl<sub>4</sub> induced hepatotoxicity in goat liver slice Culture. Asian Journal of Plant Science and Research 2016: 6(6): 10-17
- Desouza N, Villar LM, Garbina AJI, Rovidaa TAS and Garbina CAS: Assessment of health-related quality of life and related factors in patients with chronic liver disease. Brazil Journal of Infection Diseases 2015; 19(6): 590=95.
- Kagadi N, Ladda P, Naikwade N, Shikalgar T and Patil S: A review on hepatoprotective medicinal plants. International Journal of Pharmaceutical Sciences Review and Research 2019; 56(1): 122-32.
- Saleem TSM, Chetty CSM, Ramkanth V, Rajan ST, Kumar KM and Gautama K: A review on hepatoprotective herbs. International Journal of Research and Pharmaceutical Sciences 2010; 1(1): 1-5.
- Singh A, Bhat TK and Sharma OP: Clinical Biochemistry of Hepatotoxicity. J Clinic Toxicol 2011; S4: 1-19.
- Thonda VSS and Shivalinge GKP: Hepatotoxicity mechanisms and its biomarkers. International Journal of Pharmaceutical and Chemical Sci 2012; 1(2): 675-82.
- Eidi A, Mortazavi P, Bazargan M and Zaringhalam J: Hepatoprotective activity of Cinnamon ethanolic extract against CCl<sub>4</sub> induced liver injury in rats. EXCLI Journal 2012; 11(31): 495-507.
- Eidi A, Mortazavi P, Tehrani M and Rohani A: Hepatoprotective effects of Pantothenic Acid on Carbon tetrachloride- induced toxicity in rats. EXCLI Journal 2012; 11: 748-79.
- Kulkarni V, Madagundi S, Habbu P and Kothli P: Evaluation of endophytic fractions of *Boerhaavia diffusa* Linn Roots for hepatoprotective activity in rats. BLDE University Journal of Health Sciences 2016; 1(2): 113-19.
- Saheeda S, Hendrik N and Toma A: Zea mays stigma maydis prevents and extenuates acetaminophen-perturbed oxidative on slaughts in rat hepatocytes. Pharmaceutical Biology 2016; 54(11): 2664-73.

 Gunjegaonkar S, Kshirsagar S and Bayas J: Hepatoprotective and Antioxidant potential of *Tephrosia* purpurea in paracetamol induced hepatotoxicity. International Journal of Pharmacological Research 2016; 6(3): 104-08.

E-ISSN: 0975-8232; P-ISSN: 2320-5148

- Ramamurthy V and Gowri R: Hepatoprotective Study on Aegle marmelos leaves extract against Staphylococcus aureus intoxicated albino rats. American Journal of Phytomedicine and Clinical Therapeutics 2015; 3(2): 120-128.
- Balakrishna V and Lakshmi T: Hepatoprotective activity of ethanolic extract of *Terminalia chebula* fruit against ethanol induced hepatotoxicity in rats. Asian Journal of Pharmaceutical and Clinical Research 2017; 10(11): 55-58
- 15. Gupta S and Ved A: *Ipomoea turpethum* (Linn.) silva manso as a medicinal plant species -a review on bioactive components and pharmacological properties. Pharmacognosy Review 2017; 11(22): 158-66.
- Danladi S, Idris MA and Umar S: Review on pharmacological activities and phytochemical constituents of *Phyllanthus niruri* (Amarus). The Journal of Phytopharmacology 2018; 7(3): 341-48.
- Gunjegaonkar S, Kshirsagar S and Bayas J: Hepatoprotective and antioxidant potential of *Tephrosia* purpurea in paracetamol induced hepatotoxicity. International Journal of Pharmacological Research 2016; 6(3): 104-08.
- 18. Kavitha B, Shruthi S, Rai S and Ramachandra Y: Phytochemical analysis and hepatoprotective properties of *Tinospora cordifolia* against carbon tetrachloride-induced hepatic damage in rats. International Journal of Clinical Pharmacy 2019: 1-8.
- 19. Singh GN and Kumar N: A review on drug induced hepatotoxicity and its management by herbal drugs. World Journal of Pharmacy and Pharmaceutical Sciences 2017, 6(8): 446-71.

### How to cite this article:

Kagadi NM, Ladda PL and Naikwade NS: Evaluation and comparison of hepatoprotective activity of livsplin syrup and li-verve tonic formulations against carbon tetrachloride induced hepatotoxicity in rats. Int J Pharm Sci & Res 2020; 11(8): 4010-16. doi: 10.13040/IJPSR.0975-8232.11(8).4010-16.

All © 2013 are reserved by the International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to Android OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)